Since FAK/Src also plays a key role in tumor angiogenesis (56), future research should focus on the inhibition of tumor angiogenesis by glabridin through its effect on FAK/Src, to assess its novel potential as a therapeutic strategy. This evidence concerns the gene PTK2 and neoplasm.